NEW YORK (GenomeWeb) – Geneseq Biosciences and Australian Clinical Labs today announced a partnership to commercialize a noninvasive melanoma test.

The partners will offer the blood-based test, called Melaseq, which was developed by Geneseq for detecting melanoma signatures. Tissue samples can also be used for Melaseq, they said.